Eskazan, A. E. Et Al. 2014. First line treatment of chronic phase chronic myeloid leukaemia patients with the generic formulations of imatinib mesylate. BRITISH JOURNAL OF HAEMATOLOGY , vol.167, no.1 , 139-141.

Eskazan, A. E., Ayer, M., Kantarcioglu, B., Arica, D., Demirel, N., Aydin, D., ... Yalniz, F. F.(2014). First line treatment of chronic phase chronic myeloid leukaemia patients with the generic formulations of imatinib mesylate. BRITISH JOURNAL OF HAEMATOLOGY , vol.167, no.1, 139-141.

Eskazan, Ahmet Et Al. "First line treatment of chronic phase chronic myeloid leukaemia patients with the generic formulations of imatinib mesylate," BRITISH JOURNAL OF HAEMATOLOGY , vol.167, no.1, 139-141, 2014

Eskazan, Ahmet E. Et Al. "First line treatment of chronic phase chronic myeloid leukaemia patients with the generic formulations of imatinib mesylate." BRITISH JOURNAL OF HAEMATOLOGY , vol.167, no.1, pp.139-141, 2014

Eskazan, A. E. Et Al. (2014) . "First line treatment of chronic phase chronic myeloid leukaemia patients with the generic formulations of imatinib mesylate." BRITISH JOURNAL OF HAEMATOLOGY , vol.167, no.1, pp.139-141.

@article{article, author={Ahmet Emre Eskazan Et Al. }, title={First line treatment of chronic phase chronic myeloid leukaemia patients with the generic formulations of imatinib mesylate}, journal={BRITISH JOURNAL OF HAEMATOLOGY}, year=2014, pages={139-141} }